Winnebago Launches Thrive: A Bold New Direction in Towable RVs
Winnebago Thrive - Exterior
Winnebago Thrive Bunk House Front to Back View
Winnebago Thrive Back to Front View
MIDDLEBURY, Ind., May 30, 2025 (GLOBE NEWSWIRE) -- Winnebago®, a pioneer in recreational vehicles for over six decades, proudly announces the launch of the all-new Thrive™, a high-quality, lightweight, modern travel trailer developed to redefine comfort and design expectations in its category. Thrive represents a renewed energy for the Winnebago brand, reflecting a commitment to delivering innovative, customer-focused RV experiences that elevate owners' time outside.
Launching with two debut floorplans, the 18FBS and 22MBH, Thrive offers options ranging from 22 to 33 feet in length with one to two slide-outs, designed to suit a wide range of lifestyles—from weekend adventurers to full-time explorers.
'Thrive is more than a travel trailer—it's a statement,' said Adam Gudger, Product Manager for Winnebago's towables Thrive product. 'We identified an opportunity to serve design-conscious buyers seeking a refined, upscale experience— without making things complicated. Thrive fills that space with thoughtful craftsmanship, innovative features, and styling that surprises in all the right ways.'
Why Just Camp, When You Can Thrive?Thrive is built around the belief that premium outdoor living shouldn't be a compromise. It addresses a growing consumer desire for easy, elevated comfort while introducing a new class of laminated towables that offer more comfort, more flexibility and more intentional design than other travel trailers on the market.
Every door and drawer throughout Thrive features soft-close technology, complemented by thoughtful residential details like roller blackout shades, integrated utensil organizers, and pull-out recycling bins—ensuring the comfort inside is every bit as refined as the experience outside. Each Thrive travel trailer is built with core features that exceed customer expectations, including:
Scenic Design: Large windows throughout, including a new frameless panoramic front window with LED trim lighting, bring in natural light and the beauty of the outdoors
Residential Comfort: A residential comfort king bed with built-in storage, recessed ceiling lighting, bedside reading lights and blackout roller shades creates a restful retreat at day's end.
New, U.S.-built Furniture Line: An exclusive seating collection crafted in the U.S. and inspired by high-end residential design, offers a sleek, tailored aesthetic paired with the plush comfort today's glampers crave.
State-of-the-Art Kitchen: Sleek fiberglass countertops with integrated sinks, built-in utensil drawers, soft-close cabinets and pull-out pantry and trash systems make cooking a joy.
Next-Level Tech and Utility: JBL® Bluetooth® indoor/outdoor speakers, stackable washer/dryer prep on select floorplans, and power stabilizer jacks makes for effortless setup while enjoying the comforts of home.
Thrive underwent rigorous validation testing at Transportation Research Center (TRC), one of the country's top automotive proving grounds—where every component, from the slide-outs to the frameless front window to the soft-close cabinetry, proved its strength and staying power.
'Thrive reflects how people want to live and travel today,' said Grant Smith, Product Manager for Winnebago's towables unit. 'It's not just about getting from point A to point B—it's about having a space that makes every trip feel like an upgrade. And this is just the beginning. We have a full lineup of thoughtfully designed floorplans on the horizon that will expand the possibilities for how and where campers can enjoy the outdoors.'
Thrive will begin arriving at Winnebago dealerships nationwide starting late May through early June, just in time for the summer travel season. For more information, to view floorplans, or to locate a dealer, visit www.winnebago.com.
About WinnebagoWinnebago is an iconic outdoor lifestyle brand that has been building industry-leading recreational vehicles since 1958. From motorhomes to travel trailers, every product is built with pride and precision, and backed by a commitment to quality, service, and community. For more information, visit www.winnebago.com. Winnebago is a wholly owned subsidiary of Winnebago Industries (NYSE:WGO), a manufacturer of premium leisure travel and outdoor recreation products under the five brands: Winnebago, Grand Design, Chris-Craft, Newmar and Barletta. For access to Winnebago Industries' investor relations material or to add your name to an automatic email list for company news releases, visit http://investor.wgo.net.
Media Contact:Christine Bear | Marketing Manager, Winnebago cebear@winnebagoind.com 317-364-5301
Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/557e2600-6372-4148-8166-ecc0c7c6054a
https://www.globenewswire.com/NewsRoom/AttachmentNg/070b993a-5ce6-4652-8462-2ff32900e7f7
https://www.globenewswire.com/NewsRoom/AttachmentNg/c1169e22-9915-4260-9a9b-1f59ef5d128f
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO
Data Highlights Transformative Promise of CAR T in Solid Tumors Phase 1 Trial with ALLO-316 Demonstrated Potential to Provide Meaningful Clinical Benefit in Patients with CD70 TPS ≥ 50% Advanced or Metastatic RCC A Single Dose of ALLO-316 Achieved a 31% Confirmed Response Rate Four of Five Confirmed Responders Remain in Response Including One Ongoing Remission Over 12 Months Robust Expansion, Persistence, and Tumor Infiltration of ALLO-316 Seen with Standard Lymphodepletion, Showcasing Dagger® Technology as a Next-Generation Allogeneic Platform Phase 1 Safety Profile was Manageable; Proactive Diagnostic and Management Strategies Proved Effective in Mitigating IEC-HS While Preserving Efficacy SOUTH SAN FRANCISCO, Calif., June 01, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, presented updated data from the Phase 1 TRAVERSE study of ALLO-316 in renal cell carcinoma (RCC) during an oral presentation at the 2025 ASCO Annual Meeting. The Phase 1 TRAVERSE trial enrolled patients with advanced or metastatic renal cell RCC. Leveraging the proprietary Dagger® technology to enable robust CAR T cell expansion, it stands as the first and only allogeneic CAR T product to show promise in treating solid tumors. The presentation focused on the Phase 1b expansion cohort from the Phase 1 TRAVERSE study in which patients were treated with a standard regimen of cyclophosphamide and fludarabine followed by a single dose of 80 million AlloCAR T™ cells. 'ALLO-316 is showing clear evidence of targeted antitumor activity in patients who had failed most or all approved therapies for advanced or metastatic renal cell carcinoma,' said Zachary Roberts, M.D., Ph.D., EVP, Research and Development and Chief Medical Officer at Allogene. 'Our proprietary Dagger technology allows the use of a standard cyclophosphamide and fludarabine-based lymphodepletion regimen with a single dose of ALLO-316. Strong CAR T-cell kinetics and extensive infiltration of tumor tissue by CAR T cells are combining to generate deep and durable remissions. These are results that were previously considered out of reach for patients with advanced solid tumors.' 'Patients diagnosed with advanced or metastatic renal cell carcinoma often face a median survival in months after exhausting standard therapies,' said Samer A. Srour, MB ChB, MS, Associate Professor of Stem Cell Transplantation and Cellular Therapy at The University of Texas MD Anderson Cancer Center and lead investigator of the TRAVERSE trial. 'These updated results from a larger cohort of patients with confirmed CD70 positive tumors provide compelling evidence that treatment with ALLO-316 can reduce tumor burden, control disease, and in some cases deliver durable responses. These findings underscore the clinical promise of an allogeneic CAR T to address the significant unmet needs in solid tumors and offer hope to patients who have exhausted other options.' In the Phase 1b expansion cohort, 22 patients whose tumors had progressed on multiple prior therapies were treated with lymphodepletion and 20 were treated with ALLO-316. All patients had tumors resistant to immune checkpoint blockers and at least one tyrosine kinase inhibitor (TKI), 82% had ≥2+ prior TKI, and 41% had prior belzutifan. Sixteen of the ALLO-316 treated patients had a high CD70 Tumor Proportion Score (TPS >50%). The Phase 1b expansion cohort evaluated the safety and efficacy of ALLO-316 at DL2 (80M CAR T cells) following a standard FC lymphodepletion regimen (fludarabine (30 mg/m2/day) and cyclophosphamide (500 mg/m2/day) for 3 days). The median time from enrollment to the start of therapy was four days. A single dose of ALLO-316 stabilized or reversed disease progression in the majority of patients. In the 16 patients with CD70 TPS ≥50%, the trial demonstrated a Confirmed Overall Response Rate (ORR) of 31% with 44% achieving a minimum of 30% reduction in tumor burden. Of the five confirmed responders, four maintain ongoing responses, with one in sustained remission for over 12 months. The median duration of response (mDOR) has not yet been reached, indicating the potential for long-term disease control. CD70+ patients Phase 1b(N=20) ORR (confirmed CR or PR per RECIST v1.1), n/N (%) 5/20 (25) CD70 TPS ≥50%CD70 TPS <50% 5/16 (31)0/4 (0) RECIST v1.1, Response Evaluation Criteria in Solid Tumors, version 1.1; TPS, tumor proportion score The safety profile of ALLO-316 was manageable and consistent with lymphodepletion and an active CAR T product. The most frequent Grade ≥3 events were hematologic and there were no treatment-related Grade 5 events. The most common all-grade adverse events were cytokine release syndrome (CRS) (68%; with no grade ≥3), neutropenia (68%), decreased white blood cell count (68%), anemia (59%), and thrombocytopenia (55%). Immune effector cell-associated neurotoxicity syndrome (ICANS) was 18% (with no grade ≥3) and no graft-versus-host disease (GvHD) occurred. Improved recognition of IEC-HS symptoms led to diagnosis in 36% of patients with 2 patients (9%) experiencing a short-term Grade 3 (one) or Grade 4 (one patient) event. Newly implemented diagnostic and management algorithms significantly mitigated IEC-HS, with no associated Grade 5 events. TEAEs ≥20% incidence in Phase 1b, n (%) Phase 1b (N=22a) All Grades Grade ≥3 Neutropenia 15 (68) 15 (68) White blood cell count decreased 15 (68) 15 (68) Anemia 13 (59) 9 (41) Thrombocytopenia 12 (55) 6 (27) Nausea 8 (36) 0 ALT increased 7 (32) 2 (9) Peripheral edema 7 (32) 0 Pyrexia 7 (32) 0 Arthralgia 6 (27) 0 AST increased 6 (27) 2 (9) Fatigue 5 (23) 0 Headache 5 (23) 0 AEs of Special Interest Any Grade Grade ≥3 CRS 15 (68) 0 Infection 10 (45) 8 (36) IEC-HS 8 (36) 2 (9)b ICANS 4 (18) 0 Graft-versus-host disease 0 0 IEC-HS includes the preferred terms immune effector cell-associated HLH-like syndrome and Hemophagocytic lymphohistiocytosis. a Includes 2 patients who received LD but did not receive ALLO-316 b One patient experienced G4 IEC-HS based on GI bleeding with subsequent improvement and 1 patient experienced G3 IEC-HS based on hypotension managed without pressors with subsequent improvement. About ALLO-316 (TRAVERSE)ALLO-316 is an AlloCAR T™ investigational product targeting CD70, which is highly expressed in renal cell carcinoma (RCC). CD70 is also selectively expressed in several cancers, creating the potential for ALLO-316 to be developed across a variety of both hematologic malignancies and solid tumors. The ongoing Phase 1 TRAVERSE trial is designed to evaluate the safety, tolerability, and activity of ALLO-316 in patients with advanced or metastatic clear cell RCC. In October 2024 the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation based on the potential of ALLO-316 to address the unmet need for patients with advanced or metastatic RCC. The FDA previously granted Fast Track Designation (FTD) to ALLO-316 in March 2023. In April 2024, the Company announced an award from the California Institute for Regenerative Medicine (CIRM) to support the ongoing TRAVERSE trial with ALLO-316 in RCC. About Allogene TherapeuticsAllogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) products for cancer and autoimmune disease. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of 'off-the-shelf' CAR T cell product candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit and follow @AllogeneTx on X and LinkedIn. Cautionary Note on Forward-Looking Statements for Allogene This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. This press release may, in some cases, use terms such as 'develop,' 'potential,' 'expect,' 'can,' 'enable,' 'showing,' 'generate,' 'may,' 'could,' 'designed to,' 'promise,' 'hope,' 'ongoing,' 'indicating,' 'mitigate,' 'evaluate,' 'pioneer,' 'goal' or 'will,' including alternative forms thereof, or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the potential of ALLO-316 to treat patients with advanced or metastatic RCC or to provide meaningful clinical benefit in patients with advanced RCC; the potential for ALLO-316 to be developed across a variety of both hematologic malignancies and solid tumors and to generate deep and durable remissions; the potential that ALLO-316 can reduce tumor burden, control disease, and deliver durable responses; the design and potential benefits of our Dagger technology; whether the Dagger® technology will become the next-generation allogeneic platform; ALLO-316 and the Dagger technology's ability to enable robust CAR T cell expansion and persistence and tumor infiltration; the potential of ALLO-316 to address the unmet need in solid tumors or offer hope to patients who have exhausted other options; the transformative potential of our AlloCAR T™ in solid tumors; the potential advantages of the RMAT and Fast Track designation; and our ability to deliver cell therapy on-demand, more reliably, and at greater scale to more patients. Various factors may cause material differences between Allogene's expectations and actual results, including, risks and uncertainties related to: the limited nature of our Phase 1 data from our clinical trials and the extent to which such data may or may not be validated in any future clinical trials; the extent to which the Food and Drug Administration disagrees with our clinical or regulatory plans or the import of our clinical results, which could cause future delays to our clinical trials or require additional clinical trials; we may encounter difficulties enrolling patients in our clinical trials; we may not be able to demonstrate the safety and efficacy of our product candidates in our clinical trials, which could prevent or delay regulatory approval and commercialization; RMAT and Fast Track designations may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval and the designations can be revoked if the criteria for eligibility cease to be met; and challenges with manufacturing or optimizing manufacturing of our product candidates. These and other risks are discussed in greater detail in Allogene's filings with the Securities and Exchange Commission (SEC), including without limitation under the 'Risk Factors' heading in its Quarterly Report on Form 10-Q for the year ended March 31, 2025. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release. AlloCAR T™ and Dagger® are trademarks of Allogene Therapeutics, Inc. Allogene's investigational AlloCAR T™ oncology products utilize Cellectis technologies. The anti-CD70 AlloCAR T program is licensed exclusively from Cellectis by Allogene and Allogene holds global development and commercial rights to this AlloCAR T™ program. Allogene Media/Investor Contact:Christine CassianoEVP, Chief Corporate Affairs & Brand Strategy while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
2 hours ago
- Yahoo
OWNx Honors U.S. Military with Free Access to Wholesale Gold, Silver, and Platinum
Company Honors Service Members by Eliminating All Costs for Accessing Gold, Silver, and Platinum at Wholesale Pricing OWNx Honors U.S. Military with Free Access to Wholesale Gold, Silver, and Platinum Lawrence, KS , June 01, 2025 (GLOBE NEWSWIRE) -- In a bold extension of its mission to make precious metals more accessible to everyone, OWNx today announced an exclusive new initiative: all active-duty military personnel and U.S. military veterans are now eligible to receive the OWNx EDGE™ Membership completely free, gaining access to gold, silver, and platinum at wholesale cost with zero transaction or membership fees. OWNx This unprecedented offer reinforces OWNx's commitment to financial empowerment through transparency, trust, and innovation—values deeply aligned with those of the military community. "We believe that those who serve our country deserve every opportunity to build and protect their wealth with confidence and integrity," said Josh McCleary, Co-Founder and COO of OWNx. "Offering EDGE membership at no cost is our way of saying thank you and ensuring that service members and veterans can access precious metals without unnecessary fees or barriers." Industry-First Access—Now Free for Military and Veterans The OWNx EDGE™ membership—launched in April 2025—remains the first and only program of its kind in the precious metals industry. Investors typically pay $14.99 monthly or $149 annually for EDGE access. It allows members to buy fractional or whole ounces of physical gold, silver, and platinum at cost, without retail markups or hidden spreads that can range from 5-25% above spot price at traditional dealers. For the military and veteran community, this program is now entirely free for life, with no monthly charges, no commissions, and no administrative fees. Real Investment Impact for Those Who Served The savings from eliminating both membership fees and markups are substantial for military families building wealth. A $25,000 investment in gold with traditional dealers could incur $875 to $2,500 in hidden fees and markups. With free OWNx EDGE for military members, service members and veterans pay nothing beyond the actual cost of the metals, allowing them to put up to $2,400 more into actual precious metals compared to alternatives. Eligible military members and veterans gain: Access to wholesale pricing on gold, silver, and platinum with zero markup No membership fees, account fees, or transaction fees—ever. There is just a small one-time fee of $5 to cover the cost of military verification. Fractional ownership access to low-premium large bars without minimum purchase requirements Secure, insured storage in non-bank depositories in Delaware or Texas at just 0.6% per year (0.5% for IRA holdings) Easy, automated savings tools to build metal holdings over time User-friendly platform with seamless online dashboard and mobile app Full ownership of allocated metals with optional physical delivery (additional shipping costs apply) IRA integration available with OWNx Precious Metals IRA OWNx Built on Trust. Delivered with Purpose. OWNx has long been recognized for its commitment to transparency, client protection, and simplicity—offering a secure way for individuals to diversify into precious metals without hype, pressure, or opaque pricing models. Now, with this new initiative, OWNx further expands its reach to those who have served and sacrificed for the nation. The enrollment process is straightforward: military personnel and veterans can verify their service status at using standard military documentation (DD-214 for veterans, military ID for active duty) to claim their free lifetime EDGE membership. "With this offer, we're not just waiving fees—we're opening the door to a stronger, fairer financial future," added McCleary. "We're honored to support the military community with the tools and transparency they deserve, giving them access to the same institutional pricing that was previously available only to bulk purchasers." About OWNx Founded in 2008, OWNx is a pioneering platform in the precious metals market, offering secure and innovative solutions for those looking to invest in gold, silver, and platinum. With a focus on technology-driven solutions, OWNx has transformed how individuals access precious metals by providing automatic purchase options, secure storage, and instant trading capabilities, empowering people to diversify their portfolios with confidence. The company's OWNx Precious Metals IRA allows investors to include physical precious metals in their retirement planning while enjoying the benefits of EDGE membership. For more information about us, check out OWNx reviews or Military personnel and veterans can learn more about the free EDGE membership offer at ### Contact Information Josh McCleary Co-Founder and COO service@ Lawrence, Kansas newsroom: Attachment OWNx Honors U.S. Military with Free Access to Wholesale Gold, Silver, and Platinum
Yahoo
2 hours ago
- Yahoo
Folicure Hair Replacement for Men Explains How Hair Loss Affects Men's Mental Health — and Ways to Cope
Explore the deep link between male hair loss and mental health. Learn expert tips to regain confidence and tackle its emotional impact effectively. The Impact of Hair Loss on Men's Mental Health (And How to Cope) Dallas, TX, June 01, 2025 (GLOBE NEWSWIRE) -- The Impact of Hair Loss on Men's Mental Health (And How to Cope) Hair loss is a reality for many men of all ages. While it is commonly associated with aging, with 85% of men over the age of 50 experiencing noticeable hair loss, it is also normal to experience hair loss in your 20s and 30s. Hair loss is about more than just aesthetics; it can deeply affect mental health, self-esteem, and overall well-being. Fortunately, these psychological challenges don't have to feel insurmountable. This article explores the link between hair loss and mental health, highlights relevant research, and offers practical coping strategies to help men regain confidence and peace of mind. The Link Between Hair Loss and Mental Health The Broader Impact of Hair Loss For many men, hair is an integral part of their identity, symbolizing youth, vitality, and attractiveness. Losing it often feels like losing a key piece of who they are. A systematic review published in the Journal of Cosmetic Dermatology reveals how hair loss negatively impacts body image and leads to feelings of diminished social and physical attractiveness. The studies examined in the review linked hair loss to avoidance social behaviors, feelings of isolation, and even symptoms of disorders such as depression and anxiety. Research also highlights that society often associates hair loss with aging—something that can feel intimidating or undesired, especially for younger individuals experiencing early-stage baldness, and affect the way that people are treated. These psychological effects are not minor; they impact quality of life similarly to chronic dermatological conditions like eczema or psoriasis. Key Findings from the Study A pivotal study in the British Journal of Dermatology explored the burden of mental health conditions in men with alopecia areata (different from androgenetic alopecia but similar in psychological impact). The results revealed some stark findings: Men with alopecia are at significantly higher risk of developing anxiety or depression than the general population. Unemployment and decreased productivity due to mental health challenges are more common in men experiencing visible hair loss. Co-occurring conditions, like recurrent depressive episodes, appeared more frequently in men with alopecia compared to their peers without hair loss. This study underscores the urgent need for solutions addressing both the physical and emotional challenges men face with hair loss. Insights from the on Androgenetic Alopecia The Psychological Consequences of Androgenetic Alopecia study dives deeper into the emotional toll of androgenetic alopecia—the most prevalent type of hair loss in men. According to this research: Body image dissatisfaction is one of the most reported psychological consequences of hair loss. Men under 30 reported the most intense feelings of distress about their hair loss, highlighting the importance of early intervention. Behavioral coping mechanisms—such as wearing hats, obsessively worrying about appearance, or even avoiding social situations—are common responses that can exacerbate isolation. Psychological support, the study recommends, is as crucial as treating the hair loss itself. Coping Strategies and Support for Men Experiencing Hair Loss Finding ways to manage the emotional impact of hair loss is essential not only for improving mental health but also for empowering men to feel confident in their appearance. Here are practical tips to cope with hair loss: 1. Talk About It Open the conversation with trusted friends, family, or professionals. Bottling up feelings of embarrassment or frustration can amplify stress. Joining forums, online communities, or in-person support groups for men experiencing hair loss can provide camaraderie and validation. 2. Tackle Misconceptions Hair loss doesn't define your worth, attractiveness, abilities, or masculinity. Many actors and celebrities have publicly embraced their baldness, demonstrating that confidence outweighs any physical feature. Reflect on your unique characteristics and qualities beyond appearances. 3. Consider Styling Changes Find a hairstyle that makes you feel most comfortable or confident—whether that's a buzz cut, close shave, or fashionable hat. Professional grooming can help you transition if you're facing noticeable loss. 4. Prioritize Physical and Mental Well-Being A healthy diet, regular exercise, and adequate sleep can help reduce stress levels—which may exacerbate hair shedding. A balanced lifestyle can improve your overall sense of control and self-confidence. Counseling or therapy is an excellent way to address the anxiety, depression, or self-esteem issues that sometimes accompany hair loss. 5. Understand Your Options Exploring hair loss solutions can open the door to a variety of effective strategies, with non-surgical hair replacement systems being among the most accessible and versatile. These systems offer a tailored, natural look without requiring invasive procedures, making them an appealing option for individuals seeking immediate results. They can be customized to match your hair type, color, and style preferences, ensuring a seamless and confident appearance. Additionally, non-surgical systems are cost-effective and maintainable, providing a practical solution for those who prefer a reversible and adaptable approach to addressing hair loss. Finding Hope and Confidence after Hair Loss While hair loss can be emotionally challenging, it doesn't need to control how you feel about yourself or your life. By addressing its psychological impact and finding proactive solutions, men can regain confidence and improve mental well-being. Folicure understands the profound emotional and psychological impact that hair loss can have on individuals. With years of experience and expertise, they are dedicated to providing personalized hair restoration solutions that address not only the physical aspects of hair loss but also the emotional toll it takes. Their compassionate approach and commitment to innovation empower individuals to regain their confidence and take control of their appearance. Schedule a free no-obligation consultation today to connect with a team of hair replacement professions who understand what you're going through. Folicure Hair Inc. Location: Dallas, TXFollow Folicure Dallas Hair Replacement for Men Instagram Page Media Contact: az@ Attachment The Impact of Hair Loss on Men's Mental Health (And How to Cope)Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
